Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven
26 juil. 2021 02h30 HE
|
Allarity Therapeutics A/S
Lantern will reacquire global rights to Irofulven and assume full authority to manage and guide future clinical and commercial development of the program Press release Hørsholm, Denmark and...
Allarity Therapeutics Issues Share Units as Payment-In-Kind for Services Rendered During Rights Issue in Q2 2021
14 juil. 2021 11h00 HE
|
Allarity Therapeutics A/S
Issuance of share Units fullfils payment obligations to guarantors and coordinator/bookrunner of Rights Issue conducted in Q2 2021 Press release Hørsholm, Denmark (14 July 2021) Allarity...
Allarity Therapeutics Receives Acceptance & Review Notification from U.S. FDA for Pre-Market Approval Application for Dovitinib-DRP®
05 juil. 2021 14h00 HE
|
Allarity Therapeutics A/S
Administrative acceptance review notification of pre-market approval (PMA) application is first step in multi-step process conducted by the FDAThe PMA is submitted in support of an imminent new drug...
Last day of trading with Allarity Therapeutics A/S BTU
24 juin 2021 10h05 HE
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (24 June 2021) – Allarity Therapeutics A/S (“Allarity”) today announced that the recently completed Rights Issue, announced on 10 June 2021, has now been registered...
Allarity Therapeutics and Oncoheroes Biosciences to Partner on Pediatric Cancer Development of Dovitinib and Stenoparib
14 juin 2021 07h00 HE
|
Allarity Therapeutics A/S
Oncoheroes will fund and advance clinical development of both dovitinib and stenoparib in pediatric cancersAllarity is preparing to file a first U.S. new drug application (NDA) for the approval...
Allarity Therapeutics Completes Oversubscribed Rights Issue
10 juin 2021 18h01 HE
|
Allarity Therapeutics A/S
– Allarity raises SEK 102.8 million before issue costs to further finance the development of three high-priority pipeline programs – The Rights Issue of Units was subscribed for approximately 106...
Allarity Therapeutics Publishes E-Poster Detailing the Molecular Pathways Covered by the Dovitinib-DRP® Companion Diagnostic
09 juin 2021 05h08 HE
|
Allarity Therapeutics A/S
– Poster title: A novel drug response predictor (DRP®) mRNA biomarker for the multi tyrosine kinase inhibitor dovitinib – Poster provides new details of the DRP® companion diagnostic for dovitinib,...
Allarity Therapeutics Publishes Interim Report for the Period January – March 2021
28 mai 2021 07h45 HE
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (28 May 2021) Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the publication of its Interim Report for the period January – March 2021. The...
Allarity Therapeutics Publishes Prospectus Supplement
27 mai 2021 09h21 HE
|
Allarity Therapeutics A/S
Press release Hørsholm, Denmark (27 May 2021) — Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that the Company’s Board of Directors has approved a Supplement to the...
Allarity Therapeutics Secures Investment from 3i Fund for Recapitalization, Transition to Listing on U.S. Nasdaq, and Advancing Pipeline of Priority Oncology Therapeutics
21 mai 2021 01h00 HE
|
Allarity Therapeutics A/S
US $20 million investment by 3i Fund is conditioned upon completion of the recapitalization into a newly organized Delaware holding company (Allarity Therapeutics, Inc.) and a listing of its common...